Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A

NCT02175719 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT02175719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02175719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A
Lead sponsor
Eisai Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
April 16, 2013
Completion date
December 31, 2017
Enrollment
150 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical dystonia